Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

14.71 -0.09 (-0.61%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics to Participate at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For May 1, 2025
Via Benzinga
Travere Therapeutics's Earnings: A Preview
Via Benzinga
Analyst Expectations For Travere Therapeutics's Future
Via Benzinga
Earnings Scheduled For February 20, 2025
Via Benzinga
Is TRAVERE THERAPEUTICS INC (NASDAQ:TVTX) following the Minervini trend for explosive growth?
Should you consider TRAVERE THERAPEUTICS INC (NASDAQ:TVTX) for high growth investing? A fundamental and technical analysis of (NASDAQ:TVTX). 
Via Chartmill
Travere Therapeutics Reports First Quarter 2025 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics to Report First Quarter 2025 Financial Results
From Travere Therapeutics, Inc.
Via Business Wire
Assessing Travere Therapeutics: Insights From 8 Financial Analysts
Via Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via Business Wire
Novartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug Approval
The companies are going head to head in kidney disease. Here's why Novartis could have a slight advantage. 
Via Investor's Business Daily
The Analyst Verdict: Travere Therapeutics In The Eyes Of 7 Experts
Via Benzinga
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025
From Travere Therapeutics, Inc.
Via Business Wire
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Participate at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Sparks Retail Frenzy As Stock Hits Over 2-Year High On FDA Approval Plan For Kidney-Disease Drug
The company expects to submit a supplemental New Drug Application (sNDA) based on existing Phase 3 and Phase 2 data by the end of the first quarter. 
Via Stocktwits
Travere Therapeutics Skyrockets After Reaching FDA Deal For Kidney Disease Drug
The company is nearing a highly anticipated approval for a kidney disease drug. 
Via Investor's Business Daily
Lattice Semiconductor, SelectQuote, Radiant Logistics And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Provides Corporate Update and 2025 Outlook
From Travere Therapeutics, Inc.
Via GlobeNewswire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.